Parkinson’s disease (PD) is a frequent neurodegenerative disorder, characterized by motor impairment and by a wide range of non-motor symptoms, including sleep disorders, hyposmia, cognitive and affective deficits. PD is commonly treated with LDOPA, which counteracts the motor symptoms by promoting dopamine transmission.

For reasons which are poorly understood, prolonged treatment with L-DOPA results in the emergence of choreic and dystonic involuntary movements, or dyskinesia, which severely limit PD pharmacotherapy. In addition, the non-motor symptoms of PD are only in part resolved by administration of L-DOPA.

The first part of the seminar will describe a toxin based mouse model of L-DOPA-induced dyskinesia and discuss its relevance for the identification of mechanisms involved in this motor complication. The second part will focus on the use of a similar model, to identify drugs for the treatment of non-motor symptoms, with particular emphasis on memory impairment, depression and anxiety.


Professor Gilberto Fisone, Institutionen för neurovetenskap, Karolinska institutet
e-post: gilberto.fisone@ki.se


Professor Ülo Langel, Institutionen för neurokemi
e-post: ulo@neurochem.su.se